AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Bruton’s tyrosine kinase (BTK) inhibitor, Calquence (acalabrutinib), for first-line use in mantle cell lymphoma ...
The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback